FDA Approves Eylea Hd (Aflibercept) Under Material Threat MCM Priority Review Voucher
April 23, 2025
April 23, 2025
WASHINGTON, April 23 (TNSFR) -- The U.S. Department of Health and Human Services Food and Drug Administration (FDA) announced the approval of EYLEA HD (aflibercept) for the treatment of certain retinal diseases, redeeming a priority review voucher.
The approval, which was granted on August 18, 2023, for the expanded formulation of the anti-VEGF (vascular endothelial growth factor) drug, EYLEA, was issued in accordance with the Federal Food, Drug, and Cosmetic Act (FD&C Act). Th . . .
The approval, which was granted on August 18, 2023, for the expanded formulation of the anti-VEGF (vascular endothelial growth factor) drug, EYLEA, was issued in accordance with the Federal Food, Drug, and Cosmetic Act (FD&C Act). Th . . .